marburg and ebola virus vaccines
Marburg and Ebola, known as hemorragic filoviruses, are two of the deadliest viruses known to mankind. Infection by these deadly filoviruses has led to nearly 90% mortality rates in recent outbreaks.
GenPhar’s trivalent Marburg vaccine proved 100% effective in US Army (USAMRIID) challenges by all three types of Marburg virus at over 1000x times the lethal dose. No signs of hemorrhagic disease, side effects or liver damage were found.
In similar USAMRIID challenges, GenPhar's bivalent Ebola vaccine also showed 100% efficacy with no viremia, side effects or liver damage.
GenPhar is moving into human safety trials for these vaccines, and is currently working with USAMRIID to develop and test a pan-filovirus vaccine that will protect against all five subtypes of these deadly viruses.
dengue virus vaccine
Dengue is an infectious disease of acute concern to military and civilian health authorities throughout the world. GenPhar's multivalent capability is particularly valuable in making a useful dengue vaccine because of the widespread presence of four dengue subtypes and the immune priming effect caused by an initial dengue infection.
GenPhar is collaborating with the US Navy (NMRC) to conduct final challenge testing of the tetravalent dengue vaccine and is enroute for GLP production.
human immunodeficiency virus vaccine
The Division of AIDS (DAIDS) Simian Vaccine Evaluation Unit (SVEU) of the National Institutes of Allergy and Infectious Diseases (NIAID) assessed humoral and cellular immunogenicity of one of our leading HIV vaccine candidates in non-human primates. GenPhar's vaccines proved superior to competing vaccine candidates.
GenPhar is interested in building partnerships to seek approval for, manufacture and market GenPhar's HIV vaccine in the US and internationally.
hepatitis b and hepatitis c virus vaccines
GenPhar has multivalent vaccines against American and Asian strains of HBV and HCV. The company is working with an international joint venture and seeks additional domestic and international partners to conduct final testing, approval, manufacturing and marketing of these vaccines.
Initially, GenPhar's HBV and HCV vaccines will be introduced to the Asian market, where a large portion of the population suffers from chronic hepatitis B, a deadly disease for which there is no affordable, effective medication.
In addition to the vaccines above, GenPhar’s R&D team is performing pre-clinical studies on several vaccines against a variety of infectious and chronic diseases.
GenPhar actively develops partnerships and seeks additional opportunities to offer its vaccines to the worldwide market. For more information about our ongoing vaccine projects or partnership opportunities, please contact us.